Search

everythinglearnresearchcommunity

for

Search:↓

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

The drug combination was safe and showed promise in treating advanced tumors.

The combination treatment showed a higher response rate but no significant survival benefits.

New male hormonal contraceptives show promise but need more research on long-term effects and funding for larger trials.

Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Bendamustine combined with rituximab is an effective and well-tolerated treatment for certain types of lymphoma.

Clascoterone is a new, effective, and safe acne treatment without systemic side effects.

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

The consensus document recommends a comprehensive treatment plan for Hidradenitis Suppurativa, including various medications, surgery, lifestyle changes, and the need for more research and resources.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.

Liposomal anthracyclines are effective and safer for treating multiple myeloma, especially in elderly patients.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.

New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Fat-derived stem cell therapies can potentially increase hair growth and thickness in people with hair loss.

Fat-derived stem cell therapies can potentially increase hair growth and thickness in people with hair loss.

Light-based treatment, Photobiomodulation, shows promise for non-invasive skin therapy with few side effects.